Search - tctmd.com

Displaying 21 - 35 of 35

Sort: Relevancy | Date

News Conference News EAS 2020

Just One-Third of European Patients Get to LDL Cholesterol Goals

Michael O'Riordan

October 13, 2020

News Daily News

US Poverty Drives CVD in Low-Income Adults Beyond Traditional Risk Factors

L.A. McKeown

May 28, 2020

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Daily News

Cardiometabolic Risk Factors May Boost Effects of Air Pollution, Chinese Study Says

L.A. McKeown

March 12, 2019

News Daily News

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Michael O'Riordan

October 25, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

LPA Variants Linked With CHD Events in Statin-Treated Patients

Michael O'Riordan

May 03, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Michael O'Riordan

December 12, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

Advertisement

Just One-Third of European Patients Get to LDL Cholesterol Goals

US Poverty Drives CVD in Low-Income Adults Beyond Traditional Risk Factors

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

Cardiometabolic Risk Factors May Boost Effects of Air Pollution, Chinese Study Says

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

LPA Variants Linked With CHD Events in Statin-Treated Patients

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content